NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · MID CAP
Cronos Group Inc. CRON
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$146.6M
▲ 24.6% vs FY2024
EPS · FY25
$-0.02
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-0.9%
Net margin · FY25
-6.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 146.6M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 6 cents on every revenue dollar this year.
Per share
USD -0.02
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-0.9%
Return on equity, FY2025
ROE
Operating margin-11.9%
Net margin-6.4%
Return on assets-0.8%
Each USD of equity lost 1 cents this year.
Returned to shareholders
USD 9.7M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 9.7M
Share of profit-103.1%
Consecutive raises—
USD 9.7M in buybacks went back to shareholders in a year without profit.
Growth
+25.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+19.1%
+25.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.38B
Shares outstanding, FY2025
Change, 5 years+5.9%
Change, 10 years—
The share count grew 6% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.2B
total assets, end of FY2025
Total assetsUSD 1.2B
EquityUSD 1.1B
CashUSD 791.8M
Current ratio19.59×
Equity funds 91% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.1
−0.1
−0.1
−0.3
−0.2
−0.2
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.1
−0.3
−0.2
−0.1
−0.0
−0.0
Income tax $B
−0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.0
0.0
−0.1
−0.2
−0.4
−0.1
1.2
−0.0
−0.0
EPS, diluted $
−0.02
0.11
−0.19
−0.45
−1.07
−0.21
3.33
−0.12
−0.01
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−0.9
3.8
−6.6
−13.6
−26.0
−4.2
122.9
−14.6
·
Shares out B
0.38
0.38
0.38
0.38
0.37
0.36
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed